Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 12;13:213. doi: 10.1186/1476-4598-13-213

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Leccia et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

CD338-positive cells display a selective advantage in vivo . (a) HCC1937 cells were injected subcutaneously into the left and right flanks of five NOD/SCID mice. Dot plots show the percentages of CD338^high cells in the cell suspensions obtained from digestion of tumor tissues. (b) Gating strategy to analyze by flow-cytometry the expression of CD338 cells in the excised tumors. Percentages of the CD338^high cell subpopulation were determined in viable (SYTOX^-), human (HLA-ABC⁺), epithelial (EpCAM⁺) gated cells. (c) Enrichment of CD338-positive cells in CD24⁺-cell derived tumors. HCC1937 CD24⁺ and CD24^- cell subpopulations were xenografted into NOD/SCID mice. CD338^high expressions were assessed in the viable (SYTOX^-) human, (HLA-ABC⁺), epithelial (EpCAM⁺) gated tumor-derived cells.